AMED

President Mishima Kazuo oversees AMED's strategic allocation of its $1.25 billion annual budget. Programmatic funding decisions are guided by agency-wide review committees and scientific advisory panels composed of external experts, convened under AMED's Department of Research and Development Promotion. Major grants are peer-reviewed, with final authority resting with senior agency leadership.

AMED does not source proprietary deal flow in the investor sense, but designs directed funding calls in areas of national strategic interest such as regenerative medicine, genomic medicine, and pandemic preparedness. The agency also draws on the research pipelines of Japan's leading universities and national research institutes — University of Tokyo, Kyoto University, RIKEN — whose proposals flow into AMED's integrated grant management system.

It is neither. AMED is an Incorporated Administrative Agency under the Japanese government's National Strategic Special Zone framework. It functions as a funding and coordination body for biomedical translation, blending features of a research council, a grant-making foundation, and an industrial-policy accelerator.

AMED operates almost entirely through direct grants, contracts, and consortia funding. It does not operate as a limited partner in venture capital funds, but its programs frequently co-fund projects alongside pharmaceutical companies and medical device manufacturers under formal collaboration agreements.

AMED covers the full translational arc from preclinical proof-of-concept through Phase II clinical trials. Its programs are segmented by translational stage: basic science with clinical intent (AMED-CREST), applied translational projects, and clinical research trial enabling. It generally does not fund late-stage Phase III regulatory trials or commercial manufacturing.

AMED was explicitly modeled in part on the NIH, but operates on a smaller scale and with a tighter focus on translational, rather than broad basic, science. It has formal memoranda of cooperation with the NIH, the UK's Medical Research Council, and Canada's CIHR, and funds Japanese participation in international collaborative programs.

AMED's approximately $1.25 billion annual budget is appropriated by the Japanese government and draws from multiple ministries. This consolidation is AMED's core structural innovation — before 2015, similar funding was dispersed across MEXT, MHLW, and METI without coordination.